Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation
2008; NIHR Journals Library; Volume: 12; Issue: 11 Linguagem: Inglês
10.3310/hta12110
ISSN2046-4932
AutoresYen‐Fu Chen, Paresh Jobanputra, Pelham Barton, Sara E. Bryan, A Fry-Smith, Gerald J. Harris, Robert Taylor,
Tópico(s)Pharmacogenetics and Drug Metabolism
ResumoDeclared competing interests of authors: P Jobanputra has received funding from Pfizer for two research studies: 'quality of care in patients with musculoskeletal pain who use NSAIDs' and 'perception of risk in relation to NSAID use for patients with RA and OA'.He has also been entertained, paid to speak and provided with financial assistance for educational purposes by many manufacturers of non-steroidal anti-inflammatory drugs
Referência(s)